Managing opioid addiction with buprenorphine

American Family Physician

Volumn 73, Issue 9, 2006, Pages 1573-1578

  Donaher, Paul A ^a,b   Welsh, Christopher ^b  

^a University of Maryland School of Medicine ^*

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CARBAMAZEPINE; CLONIDINE; DICYCLOVERINE; HYDROXYZINE; IBUPROFEN; LOPERAMIDE; MACROLIDE; METHADONE; MU OPIATE RECEPTOR AGONIST; NALOXONE; OPIATE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRAZODONE;

ABDOMINAL CRAMP; AGITATION; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; GENERAL PRACTITIONER; HEPATITIS B; HEPATITIS C; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MYALGIA; OPIATE ADDICTION; PRESCRIPTION; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; URINE RETENTION; WITHDRAWAL SYNDROME;

AMBULATORY CARE; BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTIONS, DRUG; TREATMENT OUTCOME; UNITED STATES;

EID: 33744483991     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. United States Office of national Drug Control Policy. The president's national drug control strategy, 2002. Accessed online May 25, 2005, at: http://www.whitehousedrug policy.gov/publications/policy/03ndcs/index.html.
2. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95.
3. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
4. Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA 2000;283:1337-9.
5. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-16.
6. Drug Addiction Treatment Act of 2000, 21USC, §3501 (2000). Accessed online, October 12, 2005, at: http://buprenorphine.samhsa.gov/data.html.
7. Mendelson J, Upton RA, Everhart ET, Jacob P III, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997;37:31-7.
8. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. Human Pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996;20:369-78.
9. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984;12:577-81.
10. Suboxone Web site. Learn more about Suboxone. Accessed online May 25, 2005, at: http://www.suboxone.com.
11. Gowling L, Ali R, White J. Burprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2004;(4):CD002025.
12. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995;40:17-25.
13. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998;93:475-86.
14. Krook AL, Brors O, Dahlberg J, Grouff K, Magnus P, Roysamb E, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002;97:533-42.
15. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N engl J Med 2003;349:949-58.
16. Mattick RP, Breen C, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002207.
17. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone for opioid dependence. J Nerv Ment Dis 1993;181:358-64.
18. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54:713-20.
19. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96:683-90.
20. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001;96:267-72.
21. Buprenorphine: an alternative to methadone. Medical Letter Drugs Ther 2003;45:13-5.
22. Connaughton JF, Reeser D, Schut J, Finnegan LP. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977;129:679-86.
23. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(suppl):S87-101.
24. Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103.
25. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J, for the Manif 2000 Study Group. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000;14:151-5.
26. Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, et al., for the Manif 2000 Study Group. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug Alcohol Depend 2000;60:51-4.
27. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998;26:257-60
28. Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-50.
29. McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville, Md.: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 2004. Treatment improvement protocol (TIPS) series.